Skip to main content
. 2023 Nov 7;101(19):e1873–e1883. doi: 10.1212/WNL.0000000000207791

Figure 3. Associations Between Pretreatment sNfL Levels and Clinical and Subclinical Disease Activity on the First-Line Therapy, Need for Second-Line Therapy, and EDSS 2 Years After MS Onset.

Figure 3

Higher pretreatment sNfL levels up to 3 months before therapy initiation in patients ≥11 years were associated with a relapse (A) or new T2 lesion development (B) within the first 12 months of first-line therapy with IFN-β/GA. Patients with a clinical onset ≥2009 who had higher pretreatment sNfL levels were more likely to receive a high-efficacy therapy during the follow-up (C). Although most patients had no disability 2 years after onset, EDSS 2–4 was associated with higher pretreatment NfL concentrations (D). Boxplots depict median and interquartile range with whiskers extending to minimum and maximum values. EDSS = Expanded Disability Status Scale; GA = glatiramer acetate; IFN-β = interferon-beta; MS = multiple sclerosis; sNfL = serum neurofilament light chain.